Compare ESP & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | FHTX |
|---|---|---|
| Founded | 1928 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 111.1M |
| IPO Year | 1995 | 2020 |
| Metric | ESP | FHTX |
|---|---|---|
| Price | $52.03 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.17 |
| AVG Volume (30 Days) | 31.4K | ★ 1.2M |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 28.81 | 25.32 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $46,124,325.00 | $30,909,000.00 |
| Revenue This Year | $13.61 | N/A |
| Revenue Next Year | $5.53 | $15.98 |
| P/E Ratio | $13.20 | ★ N/A |
| Revenue Growth | 4.95 | ★ 36.75 |
| 52 Week Low | $36.82 | $1.79 |
| 52 Week High | $74.77 | $7.61 |
| Indicator | ESP | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.55 | 25.12 |
| Support Level | $48.80 | $1.79 |
| Resistance Level | $56.77 | $5.27 |
| Average True Range (ATR) | 1.89 | 0.14 |
| MACD | -0.81 | 0.11 |
| Stochastic Oscillator | 10.46 | 61.43 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.